Risedronate 5 mg/day probably leads to lower non‐vertebral fractures compared with placebo (moderate certainty).
Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).
Febuxostat 40 mg/day showed no clear difference in incidence of gout flares compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
Febuxostat 40 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).
Febuxostat 40 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).
Febuxostat 40 mg/day showed no clear difference in serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
Febuxostat 80 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).
The review found no eligible studies for this question.
Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (low certainty).